Key result
Post-MI NSAID use linked to ~600% greater risk of CV and bleeding events.
Why the study?
Limited data were available regarding the risk for adverse clinical events with concomitant NSAID treatment after myocardial infarction.
Does concomitant NSAID treatment increase thromboembolic cardiovascular and bleeding events in patients with first diagnosed MI?
Cohort (n=108,232)
Yes
Does concomitant NSAID treatment increase thromboembolic cardiovascular and bleeding events in patients with first diagnosed MI?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The study demonstrated new evidence to use COX-2 inhibitors as an alternative if NSAIDs are unavoidable in patients with acute myocardial infarction. Also, the study accurately presented the risk level of cardiovascular and bleeding events in the use of NSAIDs.”
“It is academically meaningful that the study presented new treatment strategies and evidence for a larger population group, beyond the existing studies centered only on Western population.”
Concomitant NSAID treatment after MI significantly increases the risk of cardiovascular and bleeding events, though celecoxib and meloxicam may carry the lowest risk if use is unavoidable.
BACKGROUND Limited data are available regarding the risk for adverse clinical events with concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment after myocardial infarction (MI). OBJECTIVES The aim of this study was to investigate the risk for cardiovascular and bleeding events according to groups of antithrombotic medications and subtypes of NSAIDs in patients with MI. METHODS This was a nationwide cohort study to enroll a study population from the Health Insurance Review and Assessment Service database in Korea between 2009 and 2013. Patients were divided into groups on the basis of the prescribed antithrombotic medications. The primary and secondary outcomes were thromboembolic cardiovascular and clinically relevant bleeding events. The risk for adverse clinical events was assessed by ongoing NSAID treatment and subtypes of NSAIDs. RESULTS In total, 108,232 patients (mean age 64.2 ± 12.8 years, 72.1% men, mean follow-up duration 2.3 ± 1.8 years) with first diagnosed MI were enrolled. Concomitant NSAID treatment significantly increased the risk for cardiovascular events (hazard ratio [HR]: 6.96; 95% confidence interval [CI]: 6.24 to 6.77; p < 0.001) and bleeding events (HR: 4.08; 95% CI: 3.51 to 4.73; p < 0.001) compared with no NSAID treatment. Among NSAID subtypes, the risk for cardiovascular and bleeding events was lowest with the use of celecoxib (HR: 4.65; 95% CI: 3.17 to 6.82; p < 0.001, and 3.44; 95% CI: 2.20 to 5.39; p < 0.001, respectively) and meloxicam (HR: 3.03; 95% CI: 1.68 to 5.47; p < 0.001, and 2.80; 95% CI: 1.40 to 5.60; p < 0.001, respectively). CONCLUSIONS Concomitant NSAID treatment significantly increased the risk for cardiovascular and bleeding events after MI. Although NSAID treatment should be avoided after MI, celecoxib and meloxicam could be considered as alternative options in cases in which NSAID use is unavoidable.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2020) conducted a cohort in Myocardial Infarction (n=108,232). Concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment vs. No NSAID treatment was evaluated on Thromboembolic cardiovascular events (HR 6.96, 95% CI 6.24 to 6.77, p=<0.001). Concomitant NSAID treatment after MI increased the risk for cardiovascular events and bleeding events compared with no NSAID treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: